Wednesday, July 8, 2026

pharma · HNSCC · Squamous Cell Carcinoma of the Skin · PHIO

Phio Pharmaceuticals

Phio Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

King of Prussia, USA HQ
2012 Founded
15 Employees
Public company Type
PHIO · NYSE Ticker
Company details
Status
Public
HQ
King of Prussia, USA
Founded
2012
Employees
15
Programs
2
Drugs
0
Patents
39
Intelligence · Clinical Programs

Phio Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Phio Pharmaceuticals.

Phio Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. DP CD8 TIL

    Phio Pharmaceuticals

    HNSCC

    phase 1 mab active

    1 trial
  2. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Phio Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.